Study Summary
This trial is testing different ways to help men with prostate cancer make lifestyle changes before surgery. The goal is to see if these changes can improve outcomes.
- Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 17 Secondary · Reporting Duration: 1 year, 2 years and 3 years post surgery
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
Arm A: Reference Group
1 of 4
Arm C (Arm A + Diet)
1 of 4
Arm D (Arm A + Exercise + Diet)
1 of 4
Arm B (Arm A + Exercise)
1 of 4
Active Control
Experimental Treatment
200 Total Participants · 4 Treatment Groups
Primary Treatment: Exercise and Diet · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is the enrollment period still open for this investigation?
"Correct. Data hosted on clinicaltrials.gov reveals that this research is recruiting, having been posted on May 11th 2018 and last updated August 11th 2022. The project requires 200 volunteers to be enrolled at a single site." - Anonymous Online Contributor
What is the primary purpose of this investigation?
"This trial aims to evaluate the Annual Prostate-Specific Antigen Recurrence Rate over a 6 and 24 month period. Secondary objectives include gauging changes in social support, mRNA expression patterns between biopsy and radical prostatectomy tissue samples, as well as scores on the General Depression Scale of Patient Reported Outcomes Measurement Information System (PROMIS)." - Anonymous Online Contributor
How many participants are currently enrolled in this clinical experiment?
"Affirmative. According to the clinicaltrial.gov database, this medical study is actively accepting applicants who meet its criteria. The trial was first posted on May 11th 2018 and has been updated most recently on August 11th 2022; 200 patients need to be recruited from 1 centre." - Anonymous Online Contributor